Chongqing Taiji Industry (Group) Co., Ltd. (600129.SH) Latest Company News

Oct 23, 2026, 07:58 UTC
Taiji Group disclosed that its January–September 2026 main business revenue was 7.904 billion yuan, down 11.31% year over year.
Source:
- finance.sina.cn
Oct 23, 2026, 07:58 UTC
Taiji Group reported revenue of 7.176 billion yuan for the first three quarters of 2026, down 11.27% year over year, net profit of 25.7137 million yuan, down 84.50%, and an adjusted net loss of 35.2119 million yuan.
Source:
- finance.sina.cn
Oct 23, 2026, 07:58 UTC
Taiji Group reported third-quarter 2026 revenue of 2.092 billion yuan, down 13.93% year over year, and a net loss of 62.1436 million yuan, compared with a profit a year earlier; adjusted net loss was 75.3885 million yuan.
Source:
- finance.sina.cn
Sep 23, 2026, 07:33 UTC
Inner Mongolia Ar Horqin Banner Guotai Animal Husbandry Co., Ltd., a wholly owned subsidiary of Taiji Group, had its bankruptcy reorganization plan approved by the Horqin court, with Qianyi (Jiangsu) Industrial Investment Management Co., Ltd. confirmed as the reorganization investor for 41.3762 million yuan.
Source:
- finance.sina.cn
Aug 25, 2026, 09:41 UTC
Taiji Group announced its 2026 half-year results: net profit attributable to shareholders was 87.8573 million yuan, down 36.70% year-on-year.
Source:
- finance.sina.cn
Aug 10, 2026, 09:02 UTC
Taiji Group's controlling subsidiary Southwest Pharmaceutical received a drug registration certificate from the National Medical Products Administration for butorphanol tartrate injection, in specifications of 1ml:1mg and 2ml:4mg, for the treatment of cancer pain and postoperative pain.
Source:
- finance.sina.cn
Jul 20, 2026, 09:40 UTC
Taiji Group announced that Chairman Yu Min resigned and nominated Cai Maisong as a director candidate.
Source:
- finance.sina.cn

600129.SH

Taiji Group disclosed that its January–September 2026 main business revenue was 7.904 billion yuan, down 11.31% year over year.

Taiji Group reported revenue of 7.176 billion yuan for the first three quarters of 2026, down 11.27% year over year, net profit of 25.7137 million yuan, down 84.50%, and an adjusted net loss of 35.2119 million yuan.

Taiji Group reported third-quarter 2026 revenue of 2.092 billion yuan, down 13.93% year over year, and a net loss of 62.1436 million yuan, compared with a profit a year earlier; adjusted net loss was 75.3885 million yuan.

Taiji Group announced its 2026 half-year results: net profit attributable to shareholders was 87.8573 million yuan, down 36.70% year-on-year.

Taiji Group's controlling subsidiary Southwest Pharmaceutical received a drug registration certificate from the National Medical Products Administration for butorphanol tartrate injection, in specifications of 1ml:1mg and 2ml:4mg, for the treatment of cancer pain and postoperative pain.

Taiji Group announced that Chairman Yu Min resigned and nominated Cai Maisong as a director candidate.